| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGFBP6 |
| Uniprot No | P24592 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-240aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSRCPGCGQ GVQAGCPGGC VEEEDGGSPA EGCAEAEGCL RREGQECGVY TPNCAPGLQC HPPKDDEAPL RALLLGRGRC LPARAPAVAE ENPKESKPQA GTARPQDVNR RDQQRNPGTS TTPSQPNSAG VQDTEMGPCR RHLDSVLQQL QTEVYRGAQT LYVPNCDHRG FYRKRQCRSS QGQRRGPCWC VDRMGKSLPG SPDGNGSSSC PTGSSG |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IGFBP6重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**: *"Recombinant human insulin-like growth factor-binding protein 6 inhibits tumor growth and metastasis in vitro and in vivo"*
**作者**: Bach LA, et al.
**摘要**: 该研究通过大肠杆菌表达重组人IGFBP6蛋白，发现其能特异性结合IGF-2.并在体外抑制乳腺癌细胞的增殖和迁移。动物实验进一步表明，重组IGFBP6显著减少肿瘤生长和肺转移，提示其潜在治疗应用。
---
2. **文献名称**: *"Structural and functional characterization of IGFBP-6 in regulating glioma cell apoptosis"*
**作者**: Wang Y, et al.
**摘要**: 研究利用哺乳动物细胞系统表达纯化重组IGFBP6.发现其通过阻断IGF-2介导的PI3K/AKT信号通路，诱导胶质瘤细胞凋亡，为IGFBP6在神经肿瘤治疗中的作用提供机制依据。
---
3. **文献名称**: *"Expression, purification, and functional analysis of insulin-like growth factor binding protein 6 (IGFBP6) in colorectal cancer models"*
**作者**: Smith J, et al.
**摘要**: 该文献报道了重组IGFBP6在结直肠癌细胞中的抗肿瘤效应，证明其通过抑制IGF-2依赖的MAPK通路活性，降低癌细胞侵袭能力，并增强化疗药物敏感性。
---
**备注**：以上文献为示例性质，实际引用时需核对期刊名称、作者及年份。建议通过PubMed或Web of Science以关键词“IGFBP6 recombinant”搜索最新研究。
Insulin-like growth factor-binding protein 6 (IGFBP6) is a member of the IGFBP family that regulates the bioavailability and activity of insulin-like growth factors (IGFs), particularly IGF-II. It plays a critical role in modulating cell proliferation, differentiation, and apoptosis by binding to IGFs with high affinity, thereby preventing their interaction with IGF receptors. IGFBP6 is distinct among IGFBPs due to its preferential binding to IGF-II over IGF-I and its ability to function independently of IGFs in certain contexts, such as inducing apoptosis in cancer cells through caspase-dependent pathways.
Recombinant IGFBP6 protein is engineered using molecular cloning techniques, typically expressed in bacterial (e.g., *E. coli*) or mammalian cell systems to ensure proper folding and post-translational modifications. The protein consists of conserved N- and C-terminal domains responsible for IGF binding, along with a variable mid-region. Its recombinant form allows researchers to study IGF-independent mechanisms, including interactions with extracellular matrix components and cell-surface receptors, which contribute to its roles in tumor suppression, tissue development, and metabolic regulation.
Research highlights IGFBP6's dual role in cancer: it acts as a tumor suppressor in malignancies like glioblastoma and ovarian cancer by inhibiting IGF-II-mediated proliferation, while its overexpression in some stromal tissues may promote metastasis. Recombinant IGFBP6 is also utilized in diagnostic assays and therapeutic development, particularly for diseases linked to IGF signaling dysregulation, such as diabetes and certain cancers. Studies continue to explore its potential as a biomarker or therapeutic agent, emphasizing its context-dependent functions in pathophysiology.
×
